BioMarin Pharmaceutical (NASDAQ: BMRN) | Investor LawyersExperienced Investor Lawyers
BioMarin Pharmaceutical Japan BioMarin is a pharmaceutical company that develops and provides breakthrough biopharmaceuticals for rare diseases.
BioMarin's Roctavian Receives the US FDA's Approval for the Treatment of Severe Hemophilia A
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Haemophilia A - 19 - 05 - 2021 - UCLB
BioMarin settles with activist investor Elliott, adds three new independent directors and review committee | Fierce Pharma
BioMarin Announces Governance Enhancements and Value Creation Initiatives
ALERT: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – BMRN | Business Wire
Zacks Research Comments on BioMarin Pharmaceutical Inc.'s Q2 2024 Earnings (NASDAQ:BMRN) - MarketBeat
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates – THE CHANDLER PROJECT
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut | Nasdaq
BioMarin Pharmaceutical's Valrox (Valoctocogene
First Haemophilia Gene Therapy Licensed by EMA - Irish Haemophilia Society
BioMarin opens €38m expansion at Irish manufacturing site
Ben Schooler on LinkedIn: I am so proud of the whole Biomarin team (both past and present) for…
Biomarin fact sheet_022317 | PDF
Activist Investor Takes $1B Stake in BioMarin Amid CEO Change, Disappointing Sales | BioSpace
Allen Institute and BioMarin team up to develop gene therapies for rare brain diseases. - Allen Institute
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
BioMarin Pharmaceutical Inc. (BMRN) Announces Record Financial Results for 2023
BioMarin's Gene Therapy for Hemophilia A Remains on Track for US Approval
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia
PR crisis in the making at BioMarin Pharmaceutical - The American Genius
BioMarin Pharmaceutical Inc (BMRN) Stock Message Board | InvestorsHub
